IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care Reck, M., Srivastava, M. K., Wakelee, H. A., Felip, E., Altorki, N. K., Csoszi, T., Moiseyenko, V., Akopov, A., Smolin, A., Chella, A., Vallieres, E., Martinez-Marti, A., Zou, W., McNally, V., Bennett, E., Prizant, H., Nabet, B., Ballinger, M., Gitlitz, B. J., Zhou, C. LIPPINCOTT WILLIAMS & WILKINS. 2023

View details for Web of Science ID 001053772003598